Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 6/20 | 0.68 |
| ▸ | MEN1 | O00255 | 3/20 | 0.68 |
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.68 |
| ▸ | HPGD | P15428 | 2/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | ALPG | P10696 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.56 |
| ▸ | F3 | P13726 | 2/20 | 0.56 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 5/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.51 |
| ▸ | EP300 | Q09472 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6851585 | 1.00 | CYP1A2 (0.68) | CYP1A2MEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL6851634 | 0.93 | CYP2C9 (0.62) | CYP1A2MEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL6851638 | 0.93 | CYP2C9 (0.62) | CYP1A2MEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL29259516 | 0.82 | MEN1 (0.49) | CYP1A2MEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL29259517 | 0.82 | MEN1 (0.49) | CYP1A2MEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL6853627 | 0.79 | CYP2C9 (0.86) | CYP1A2MEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL6853810 | 0.79 | CYP2C9 (0.86) | CYP1A2MEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL17899520 | 0.79 | CYP1A2 (0.65) | CYP1A2MEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL29259308 | 0.78 | LY96 (0.54) | CYP1A2MEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL29259307 | 0.78 | LY96 (0.54) | CYP1A2MEN1MAPTKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6777447-B2 | ANTIINFLAMMATORY AGENTS, BACTERICIDES, OXIDATION RESISTANCE, ANTICANCER AGENTS | GADJAH MADA, FACULTY OF PHARMACY, UNIVERSITY OF, THE (ID) | 2004-08-17 | — | — | US | claimed |
| US-20030092772-A1 | Derivatives of benzylidene cyclohexanone, benzylidene cyclopentanone, and benzylidene acetone, and therapeutic uses thereof | GADJAH MADA, FACULTY OF PHARMACY, UNIVERSITY OF, THE (ID) | 2003-05-15 | — | — | US | claimed |
| US-6777447-B2 | ANTIINFLAMMATORY AGENTS, BACTERICIDES, OXIDATION RESISTANCE, ANTICANCER AGENTS | GADJAH MADA, FACULTY OF PHARMACY, UNIVERSITY OF, THE (ID) | 2004-08-17 | — | — | US | disclosed |
| US-20030092772-A1 | Derivatives of benzylidene cyclohexanone, benzylidene cyclopentanone, and benzylidene acetone, and therapeutic uses thereof | GADJAH MADA, FACULTY OF PHARMACY, UNIVERSITY OF, THE (ID) | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092772-A1 | Derivatives of benzylidene cyclohexanone, benzylidene cyclopentanone, and benzylidene acetone, and therapeutic uses thereof | GSTK1, GSTP1, CAT | CYP1A2 258/4885MEN1 4884/4885MAPT 3557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.